Total net revenue increased 20.5% to $17.6 million for third quarter of 2025 compared to the third quarter of 2024 Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ...
ZYCUBO ® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics sold its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $205 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results